I-Mab (Nasdaq:IMAB) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

IMAB 주식 개요

임상 단계의 바이오 제약 회사인 I-Mab은 주로 미국에서 면역 종양학 및 면역 염증 질환 분야의 생물학적 제제를 발굴, 개발 및 상업화하는 회사입니다.

IMAB 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

의미 있는 시가총액이 없습니다. ( $94M )

의미 있는 수익이 없습니다. ( CN¥28M )

I-Mab 경쟁사

Verastem

NasdaqCM:VSTM

US$108.3m

Cibus

NasdaqCM:CBUS

US$96.3m

vTv Therapeutics

NasdaqCM:VTVT

US$39.5m

Sage Therapeutics

NasdaqGM:SAGE

US$445.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 I-Mab
과거 주가
현재 주가	US$1.24
52주 최고치	US$2.54
52주 최저치	US$0.99
베타	1.07
11개월 변경	9.73%
3개월 변경 사항	-21.52%
1년 변경 사항	-4.62%
33년 변화	-98.29%
5년 변화	n/a
IPO 이후 변화	-90.08%

최근 뉴스 및 업데이트

Recent updates

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

Sep 13

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

Aug 30

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Aug 23

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 20

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

Jul 22

I-Mab Valuation Offers A Biotech Investment Opportunity

Jun 23

Companies Like I-Mab (NASDAQ:IMAB) Are In A Position To Invest In Growth

May 24

I-Mab Shaken By Management Moves, Merger Talk And Delisting Threat

May 06

Bearish: Analysts Just Cut Their I-Mab (NASDAQ:IMAB) Revenue and EPS estimates

Apr 01

I-Mab Founder Retakes Reins In Latest Shakeup Ahead Of Commercialization Phase

Jan 03

I-Mab Gets Boost From Latest Industry Signals On New Cancer Treatment

Oct 14

Drug Maker I-Mab Wins Plaudits As Analysts Urge Caution On Soaring Stock

Jul 02

주주 수익률

	IMAB	US Biotechs	US 마켓
7D	18.1%	-0.1%	0.8%
1Y	-4.6%	21.7%	33.4%

수익률 대 산업: IMAB 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: IMAB 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IMAB's price volatile compared to industry and market?
IMAB volatility
IMAB Average Weekly Movement	8.9%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.1%

안정적인 주가: IMAB 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IMAB 의 주간 변동성( 7% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2014	34	Sean Fu	ir.i-mabbiopharma.com

아이맙은 미국을 중심으로 면역항암 및 면역염증 질환 분야의 바이오 의약품을 발굴, 개발 및 상업화하는 임상 단계 바이오 제약 회사입니다. 고형암 치료를 위한 임상 2상 중인 CD73 중화항체 울릴리리맙, 위암 및 기타 암 치료를 위한 임상 1상 중인 이중특이항체 기바스토미그, 고형암 치료를 위한 임상 1상 중인 프로그램된 세포사멸 리간드 기반 종양 의존적 T세포 관여인자 라지스토미그를 개발하고 있다. 또한 암 면역 치료를 위한 완전 인간 CD47 단일 클론 항체인 렘조팔리맙(Lemzoparlimab) 개발 기회도 검토하고 있습니다.

I-Mab 기본 사항 요약

I-Mab 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IMAB 기본 통계
시가총액	US$93.65m
수익(TTM)	-US$205.60m
수익(TTM)	US$3.49m

28.9x

P/S 비율

-0.5x

P/E 비율

IMAB 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IMAB 손익 계산서(TTM)
수익	US$3.49m
수익 비용	US$0
총 이익	US$3.49m
기타 비용	US$209.10m
수익	-US$205.60m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.52
총 마진	100.00%
순이익 마진	-5,887.68%
부채/자본 비율	0%

IMAB 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IMAB 주식 개요

보상

위험 분석

I-Mab 경쟁사

NasdaqCM:VSTM

US$108.3m

NasdaqCM:CBUS

US$96.3m

NasdaqCM:VTVT

US$39.5m

NasdaqGM:SAGE

US$445.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Recent updates

I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024

I-Mab to Report First Half, 2024 Results on Aug 28, 2024

I-Mab Announces Board and Committee Changes

I-Mab Appoints Phillip Dennis as Chief Medical Officer

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

I-mab Biopharma (Hangzhou) Co., Ltd. completed the acquisition of I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB).

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates upgraded to CN¥12.72 loss

I-Mab: Trading Below Net Cash With Multiple Upside Options

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-mab Biopharma (Hangzhou) Co., Ltd. agreed to acquire I-Mab Biopharma (Shanghai) Co., Ltd. from I-Mab (NasdaqGM:IMAB) for $80 million.

I-Mab Announces Board Changes , Effective February 10, 2024

Member of Scientific Advisory Board notifies of intention to sell stock

Chief Legal Officer notifies of intention to sell stock

Price target decreased by 17% to US$21.56

Chief Legal Officer notifies of intention to sell stock

I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy (PMN)

I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503

New minor risk - Share price stability

Consensus revenue estimates fall by 15%

Consensus revenue estimates fall by 78%

Price target decreased by 19% to US$24.47

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab to Report First Half, 2023 Results on Aug 17, 2023

Member of Scientific Advisory Board notifies of intention to sell stock

I-Mab Announces the Appointment of Raj Kannan as Member of the Board of Directors

TRACON Pharmaceuticals, Inc. Announces Enforcement Action to Collect Binding Arbitration Award from I-Mab Biopharma

Price target increased by 8.5% to US$27.65

Interim CFO notifies of intention to sell stock

Price target increased by 7.2% to US$27.30

Price target decreased by 11% to US$29.81

Price target decreased by 7.7% to US$33.57

We're Keeping An Eye On I-Mab's (NASDAQ:IMAB) Cash Burn Rate

Member of Scientific Advisory Board notifies of intention to sell stock

Price target decreased to US$36.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues miss analyst expectations

I-Mab Announces Management Changes

I-Mab Announces Executive Changes

I-Mab: Another CD47 Inhibitor Biotech With Great Potential

I-Mab(NasdaqGM:IMAB) dropped from FTSE All-World Index (USD)

I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome

I-Mab gets Chinese nod to start phase 3 combo treatment trial for myelodysplastic syndrome

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022

Consensus revenue estimates fall by 63%

I-Mab (NasdaqGM:IMAB) announces an Equity Buyback for $40 million worth of its shares.

I-Mab Biopharma Non-GAAP EPADS of -$1.54, revenue of $7.74M

I-Mab and senior executives may buy $40M worth of shares; stock up 10%

Newsflash: I-Mab (NASDAQ:IMAB) Analysts Have Been Trimming Their Revenue Forecasts

I-Mab to Report First Half, 2022 Results on Aug 30, 2022

Consensus revenue estimates fall by 13%

Price target decreased to US$58.94

I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1Bb Bispecific Antibody TJ-CD4B in Solid Tumors in China

I-Mab doses first patient in phase 1 trial of TJ-CD4B in solid tumors in China

I-Mab Valuation Offers A Biotech Investment Opportunity

Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin Alfa for Treatment of Pediatric Growth Hormone Deficiency

Price target decreased to US$74.89